It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BHC’s FA Score shows that 1 FA rating(s) are green whileDVAX’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BHC’s TA Score shows that 4 TA indicator(s) are bullish while DVAX’s TA Score has 5 bullish TA indicator(s).
BHC (@Pharmaceuticals: Other) experienced а -16.00% price change this week, while DVAX (@Pharmaceuticals: Other) price change was -6.34% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -4.00%. For the same industry, the average monthly price growth was -2.21%, and the average quarterly price growth was -10.30%.
BHC is expected to report earnings on Apr 30, 2025.
DVAX is expected to report earnings on May 01, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
BHC | DVAX | BHC / DVAX | |
Capitalization | 3.86B | 1.62B | 238% |
EBITDA | 2.2B | 9.67M | 22,781% |
Gain YTD | -29.653 | 0.626 | -4,733% |
P/E Ratio | 13.39 | 31.63 | 42% |
Revenue | 8.76B | 232M | 3,775% |
Total Cash | 947M | 742M | 128% |
Total Debt | 22.4B | 257M | 8,716% |
BHC | DVAX | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 85 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 32 Undervalued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 47 | |
SMR RATING 1..100 | 100 | 84 | |
PRICE GROWTH RATING 1..100 | 86 | 52 | |
P/E GROWTH RATING 1..100 | 97 | 96 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BHC's Valuation (32) in the Pharmaceuticals Other industry is somewhat better than the same rating for DVAX (73) in the Biotechnology industry. This means that BHC’s stock grew somewhat faster than DVAX’s over the last 12 months.
DVAX's Profit vs Risk Rating (47) in the Biotechnology industry is somewhat better than the same rating for BHC (100) in the Pharmaceuticals Other industry. This means that DVAX’s stock grew somewhat faster than BHC’s over the last 12 months.
DVAX's SMR Rating (84) in the Biotechnology industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that DVAX’s stock grew similarly to BHC’s over the last 12 months.
DVAX's Price Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for BHC (86) in the Pharmaceuticals Other industry. This means that DVAX’s stock grew somewhat faster than BHC’s over the last 12 months.
DVAX's P/E Growth Rating (96) in the Biotechnology industry is in the same range as BHC (97) in the Pharmaceuticals Other industry. This means that DVAX’s stock grew similarly to BHC’s over the last 12 months.
BHC | DVAX | |
---|---|---|
RSI ODDS (%) | 1 day ago74% | 1 day ago85% |
Stochastic ODDS (%) | 1 day ago78% | 1 day ago79% |
Momentum ODDS (%) | 1 day ago79% | 1 day ago72% |
MACD ODDS (%) | 1 day ago70% | 1 day ago72% |
TrendWeek ODDS (%) | 1 day ago78% | 1 day ago76% |
TrendMonth ODDS (%) | 1 day ago76% | 1 day ago76% |
Advances ODDS (%) | 12 days ago75% | 11 days ago77% |
Declines ODDS (%) | 1 day ago77% | 4 days ago79% |
BollingerBands ODDS (%) | 1 day ago73% | 1 day ago77% |
Aroon ODDS (%) | 1 day ago78% | 1 day ago78% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
VFL | 10.35 | 0.10 | +0.93% |
abrdn National Municipal Income Fund | |||
SAT | 24.58 | 0.08 | +0.33% |
Saratoga Investment Corp | |||
EMCR | 29.11 | -0.59 | -1.99% |
Xtrackers EM CarbReduc&ClimtImprvs ETF | |||
QSPT | 25.78 | -1.02 | -3.80% |
FT Vest Nasdaq-100® Buffer ETF Sep | |||
BSVO | 18.20 | -1.52 | -7.71% |
EA Bridgeway Omni Small-Cap Value ETF |
A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.
Ticker / NAME | Correlation To DVAX | 1D Price Change % | ||
---|---|---|---|---|
DVAX | 100% | -0.16% | ||
ACET - DVAX | 39% Loosely correlated | -7.32% | ||
SNDL - DVAX | 35% Loosely correlated | -1.39% | ||
SUPN - DVAX | 29% Poorly correlated | -1.01% | ||
ETON - DVAX | 27% Poorly correlated | -5.73% | ||
ALKS - DVAX | 25% Poorly correlated | -3.03% | ||
More |